Eversept Partners’s Coherus Oncology CHRS Stock Holding History

Eversept Partners’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-120,036	Closed	-$1.64M	–	63
2019 Q1	$1.64M	Buy	+120,036	New	+$1.6M	0.48%	34

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Eversept Partners's CHRS Position: Q2 2019 in Review

Eversept Partners sold out of Coherus Oncology (CHRS) in Q2 2019, closing a stake of 120,036 shares — an estimated $1.64M sold.

Eversept Partners first reported a position in CHRS in Q1 2019 and held it in 1 quarter. The position peaked at $1.64M in Q1 2019. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2019.

Eversept Partners reported no remaining Coherus Oncology position as of Q2 2019 after selling out during the quarter.
Eversept Partners sold 120,036 Coherus Oncology shares in Q2 2019, an estimated $1.64M.
Eversept Partners first reported a position in Coherus Oncology in Q1 2019 and held it in 1 quarter.
Eversept Partners's Coherus Oncology position peaked at $1.64M in Q1 2019.
146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2019.

Based on Eversept Partners's 13F filing for Q2 2019, filed 13 Aug 2019.